Skip to main content

Talis Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on . Posted in Public Companies.

MENLO PARK, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (the “Company”), announced that the Company’s Board of Directors has granted an inducement award to Brian Blaser, the Company’s newly appointed Chief Executive Officer. The inducement award was granted pursuant to the Company’s 2021 Inducement Plan (the “Inducement Plan”) as an inducement material to Mr. Blaser entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement award is comprised of (i) a stock option award covering 638,144 shares of the Company’s common stock with per share exercise price equal to the fair market value of the Company’s common stock on the grant date and will be subject to vesting over five years, with 20% of the shares vesting on the one year anniversary of Mr. Blaser’s start date, and the remainder vesting monthly over the following forty-eight (48) months, subject to his continued employment and the terms and conditions of the stock option agreement, and (ii) a restricted stock unit award covering 625,000 shares of the Company’s common stock and will be subject to vesting over five years, with 20% of the shares vesting on the one year anniversary of Mr. Blaser’s start date, and the remainder vesting in a series of four equal successive annual installments on the second, third, fourth and fifth anniversaries of his start date, subject to his continued employment and the terms and conditions of the restricted stock unit award agreement.

About Talis Biomedical
Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One system to enable accurate, low cost, and rapid molecular testing. The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for use of the Talis One COVID-19 Test System in a variety of healthcare settings. For more information, visit talisbio.com.

Contact
Media & Investors
Emily Faucette
efaucette@talisbio.com 
415-595-9407

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.